Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitri, Alexander, Herbst, Friederike, Fraietta, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932053/
https://www.ncbi.nlm.nih.gov/pubmed/35303871
http://dx.doi.org/10.1186/s12943-022-01559-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932053/
https://www.ncbi.nlm.nih.gov/pubmed/35303871
http://dx.doi.org/10.1186/s12943-022-01559-z

Ejemplares similares